
Eli Lilly has announced topline results from the LIBRETTO-531 study assessing Retevmo (selpercatinib) as an initial treatment for patients with …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer

